ALGORAE PHARMACEUTICALS LIMITED (ASX: 1AI)
Health care · News and insights
1AI: $0.009 +0.00% · MC: $18M
Latest 1AI announcements
Announcement Insights
Algorae Advances Drug-Registration Pipeline as First Customer Receipts Begin
Algorae Pharmaceuticals reported early commercial progress alongside an expanding regulatory pipeline: first customer receipts arrived in the September quarter, while products under TGA review increased to seven from five. Its NSW Health supplier appointment is expected to lead to first supply in the December quarter, but carries no guaranteed orders or spending and is not expected to materially affect current-year revenue; the company also reported stronger results in a second preclinical validation of its AI platform.
Updated 17 Nov 2026, 12:31 PM Sydney time
Sources
Change of Director's Interest Notice - DHNotification regarding unquoted securities - 1AIChange of Director's Interest Notice - DH, DG, TVProposed issue of securities - 1AIAGM Chairman Address to ShareholdersResults of MeetingQuarterly Activities Report and Appendix 4C Cash Flow ReportCorporate PresentationUpdated Securities Trading PolicyComments
2026-11-17 · Health care
1AI: $0.009 +0.00% · MC: $18M
Algorae Pharmaceuticals chairman David Hainsworth acquired additional shares through an on-market trade held indirectly via Cathedral Estate, increasing that holding. The notice reports no change to his direct holdings or other disclosed interests.
Updated 2026-11-17 12:16
Sources
Change of Director's Interest Notice - DHComments
2026-11-11 · Health care
1AI: $0.009 +12.50% · MC: $18M
Algorae Pharmaceuticals issued 90 million unquoted performance rights as director remuneration after shareholder approval, completing the issue proposed the previous day. Director notices also report changes in interests linked to the rights issue; the supplied notice excerpt identifies David Hainsworth’s indirect acquisition of rights, while the other directors’ details are truncated.
Updated 2026-11-11 18:17
Sources
Notification regarding unquoted securities - 1AIChange of Director's Interest Notice - DH, DG, TVComments
2026-11-10 · Health care
1AI: $0.008 -15.79% · MC: $18M
Algorae Pharmaceuticals has shareholder approval to issue up to 90 million performance rights to directors as an incentive component of their remuneration, with the issue proposed for November 11. The rights are not being issued for cash.
Updated 2026-11-10 17:41
Sources
Proposed issue of securities - 1AIComments
2026-11-05 · Health care
1AI: $0.009 +0.00% · MC: $18M
At its AGM, Algorae Pharmaceuticals said seven product registrations are now under TGA review, up from five reported in its September-quarter update, and first customer receipts arrived during that quarter. The company also said its portfolio now exceeds 20 products and that first supply under its NSW Health arrangement is expected this quarter; shareholders passed all resolutions listed in the meeting results.
Updated 2026-11-05 13:58
Sources
AGM Chairman Address to ShareholdersResults of MeetingComments
2026-10-30 · Health care
1AI: $0.010 +0.00% · MC: $18M
Algorae Pharmaceuticals says its AI platform identified approximately 2.5 times the proportion of confirmed synergistic drug combinations achieved by its earlier model in a second independent preclinical validation. Its subsidiary AlgoraeRx was appointed one of several suppliers under a NSW Health contract, with first supply expected in the December quarter, but no minimum orders or spending are guaranteed and the company says the award alone is not expected to materially affect current-year revenue. The company also reported cash of approximately $3 million at quarter-end, with a further $3 million facility undrawn.
Updated 2026-10-30 11:49
Sources
Quarterly Activities Report and Appendix 4C Cash Flow ReportCorporate PresentationComments
2026-10-28 · Health care
1AI: $0.009 +0.00% · MC: $18M
Algorae Pharmaceuticals has lodged an updated securities trading policy, setting out dealing restrictions for directors, employees and contractors, including blackout periods and prior clearance requirements for restricted persons. The supplied excerpt does not detail other changes to the policy.
Updated 2026-10-28 18:50
Sources
Updated Securities Trading PolicyComments
Comments